Relationship between structure and neutralizing activity of rabbit tetanus antibodies elicited by acellular and whole-cell pertussis DTP vaccines

Vaccine

Volumn 16, Issue 7, 1998, Pages 672-677

  Dokmetjian, José ^a   Della Valle, Cecilia ^a   Lavigne, Victoria ^a   Eriksson, Patricia V ^a   Manghi, Marcela A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Acellular DTP vaccine; Anti tetanus antibodies; Whole cell DTP vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; NEUTRALIZING ANTIBODY;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BORDETELLA PERTUSSIS; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP; TETANUS; TETANUS TOXOID;

EID: 0032054623     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00262-4     Document Type: Article

References (46)

1. 1 Lambert, H.J. Epidemiology of a small pertussis outbreak in Kent County. Michigan Public Health Rep. 1965, 80, 365-369.
2. 2 Centers for Disease Control. Pertussis - United States 1982 and 1983. Morbid. Mortal. Wkly Rep. 1984, 33, 573-576.
3. 3 Hinman, A.R. and Koplan, J.P. Pertussis and pertussis vaccine reanalysis of benefits risks, and costs. J. Am. Med. Assoc. 1984, 251, 3109-3113.
4. 4 Miller, D.L., Alderslade, R. and Ross, E.M. Whooping cough and whooping cough vaccine: the risks and benefits debate. Epidemiol. Rev. 1982, 4, 1-24.
5. 5 Barkin, R.M. and Pichichero, M.E. Diphtheria-pertussis-tetanus vaccine: reactogenicity of commercial products. Pediatrics 1979, 63, 256-260.
6. 6 Cody, C.L., Baraff, L.J., Cherry, J.D., Marcy, S.M. and Manclarck, C.R. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981, 68, 650-660.
7. 7 Mortimer, E.A. Jr and Jones, P.K. An evaluation of pertussis vaccine. Rev. Infect. Dis. 1979, 1, 927-932.
8. 8 Sato, Y., Kimura, M. and Fukumi, H. Development of a component pertussis vaccine in Japan. Lancet 1984, 1, 122-126.
9. 9 Edwards, K.M., Bradley, R.B. and Decker, M.D. et al. Evaluation of a new highly purified pertussis vaccine in infants and children. J. Infect. Dis. 1989, 160, (5) 832-837.
10. 10 Anderson, E.L., Belshe, R.B. and Bartram, J. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. J. Infect. Dis. 1988, 157, (4), 731-737.
11. 11 Miller, E., Miller, D.L., Ashworth, L.A.E., Waight, P.A. and Harbert, K.A. Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. In: Proc. Int. Symp. on Pertussis (Ed. Manclark, C.R) [DHHS Publication No. (FDA) 90-1164:75-86]. Department of Health and Human Services, United States Public Health Service, Bethesda, MD, 1990.
12. 12 Kimura, M., Kuno-Sakai, H. and Sato, Y. et al. A comparative trial of the reactogenicity and immunogenicity of the Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Am. J. Dis. Child. 1991, 145, 734-741.
13. 13 Aoyama, T., Murase, Y., Gonda, T. and Iwata, T. Type-specific efficacy of acellular pertussis vaccine. AJDC 1988, 142, 4-42.
14. 14 Kimura, M. and Kuno-Sakai, H. Pertussis vaccines in Japan. Acta Pediatr. Jpn. 1988, 30, 143-153
15. 15 Noble, G.R., Bernier, R.H. and Esber, E.C. et al. Acellular and whole cell pertussis vaccines in Japan: report of a visit by US scientists. J. Am. Med. Assoc. 1987, 257, 1351-1356.
16. 16 Mortimer, E.A., Kimura, M. and Cherry, J.D. et al. Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Am. J. Dis. Child. 1990, 144, 899-904.
17. 17 Centers for Disease Control. Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series; update to supplementary ACIP statement. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly Rep. 1992, 41(RR-15), 1-5.
18. 18 Committee on Infectious Diseases. Acellular pertussis vaccines: recommendations for use as the fourth and fifth doses. Pediatrics 1992, 90, 121-123.
19. 19 Edwards, K.M. Acellular pertussis vaccines a solution to the pertussis problem? J. Infect. Dis. 1993, 168, 15-20.
20. 20 Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. The Lancet 1988, 1, 955-960.
21. 21 Morgan, C.M., Blumberg, D.A. and Cherry, J.D. Comparison of acellular and whole-cell pertussis component DTP vaccines. Am. J. Dis. Child. 1990, 144, 41-45.
22. 22 Blumberg, D.A., Mink, C.M. and Cherry, J.D. et al. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis component DTP vaccine in 17 to 24-month old children, with measurement of 69-kilodalton outer membrane protein antibody. J. Pediatr. 1990, 117, 46-51.
23. 23 Blumberg, D.A., Mink, C.M. and Cherry, J. et al. Comparison of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. J. Pediatr. 1991, 119, 194-204.
24. 24 Centers for Disease Control. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use-supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid. Mortal. Wkly Rep. 1992, 41, 1-10.
25. 25 Margni, R.A. Coprecipitating IgG asymmetric antibodies: a possible role for Fab glycosylation and speculations on their formation and functions in disease. Glycosyl. Dis. 1994, 1, 59-66.
26. 26 Labeta, M., Margni, R.A., Leoni, J. and Binaghi, R.A. Structure of asymmetric non-precipitating antibody: presence of a carbohydrate residue in only one Fab region of the molecule. Immunology 1986, 57, 311-317.
27. 27 Leoni, J., Labeta, M. and Margni, R.A. The asymmetric IgG nonprecipitating antibody localization of the oligosaccharide involved in that phenomenon by ConA interaction. Mol. Immunol. 1986, 23, 1397-1400.
28. 28 Miranda, S., Malan Borel, I., Dokmetjian, J., Margni, R.A. and Binaghi, R.A. Asymmetric non-precipitating antibodies in commercial hyperimmune gamma-globulin for therapeutic use. Immunology 1992, 74, 707-709.
29. 29 Margni, R.A., Parma, E., Cerone, S., Erpelding, A. and Perdigón, G. Agglutinating and non-agglutinating antibodies in rabbits inoculated with a particulate antigen (Salmonella typhimurium). Immunology 1983, 48, 351-359.
30. 30 Margni, R.A., Perdigón, G., Gentile, T. and Dokmetjian, J. IgG precipitating and coprecipitating antibodies in rabbits repeatedly injected with soluble and particulate antigens. Vet. Immunol. Immunopathol. 1986, 13, 51-61.
31. 31 Harlow, E. and Lane, D. Storing and purifying antibodies. In: Antibodies: A Laboratory Manual, Chapter 8. Cold Spring Harbor Laboratory, New York, 1988, pp. 309-311.
32. 32 Natvig, J.B. and Turner, M.W. Pepsin digestion of human G-myeloma proteins of different subclasses. II. Immunochemical investigations of the products of peptic digestion. Clin. Exp. Immunol. 1970, 7, 627-640.
33. 33 Craig, J.P. Immune response to Corynebacterium diphtheriae and Clostridium tetani: Diagnostic method. In: Manual of Laboratory Immunology, 4th edn (Eds Rose, N.R., Conway de Macario, E., Fahey, J.L., Friedman, H. and Penn, G.M.). American Society for Microbiology, Washington DC, 1992, pp. 435-439.
34. 34 Finney, D.J. Statistical Method in Biological Assay. Charles Griffin, London, 1964, Chapt. 20, p. 33.
35. 35 Heininger, U., Cherry, J.D. and Christenson, P.D. et al. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany. Vaccine 1994, 12, 81-86.
36. 36 Bernstein, H.H., Rothstein, E.P. and Pichichero, M.E. et al. Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States. Vaccine 1995, 13, 1631-1635.
37. 37 Pichichero, M.E., Green, J.L., Francis, A.B., Marsocci, S.M., Lynd, A.M. and Litteer, T. Comparison of a three-component acellular pertussis vaccine with whole cell pertussis vaccine in two-month-old children. Pediatr. Infect. Dis. J. 1994, 13, 193-196.
38. 38 Anderson, E.L., Mink, M.Ch., Berlin, B.S., Nan Shih, Ch., Tung, F.F. and Belshe, R.B. Acellular pertussis vaccine in infants: evaluation of single component and two-component products. Vaccine 1994, 12, 28-31.
39. 39 Looney, J.M., Edsall, G., Ipsen, J. and Chasen, M.D. Persistence of antitoxin levels after tetanus toxoid inoculation and effect of a booster dose after various intervals. N. Engl. J. Med. 1956, 254, 6-12.
40. 40 Margni, R.A. and Binaghi, R.A. Non-precipitating asymmetric antibodies. A. Rev. Immun. 1988, 6, 535-554.
41. 41 Gentile, T., Malán Borel, I., Angelucci, J., Miranda, S. and Margni, R.A. Preferential synthesis of asymmetric antibodies in rats immunized with paternal particulate antigens. Effect on pregnancy. J. Reprod. Immunol. 1992, 22, 173-183.
42. 42 Pasetti, M.F., Dokmetjian, J., Brero, M.L., Eriksson, P.V., Ferrero, F. and Manghi, M.A. Structure and protective capacity of tetanus and diphtheria antibodies produced during human pregnancy and transferred to new-born. Am. J. Rep. Immun. 1997, 37, 250-256.
43. 43 Simonsen, O., Schou, C. and Heron, I. Modification of the ELISA for the estimation of tetanus antitoxin in human sera. J. Biol. Stand. 1987, 15, 143-157.
44. 44 Cutts, F.T. and Begg, N. Diphtheria, pertussis, and tetanus vaccination. The Lancet 1992, 339, 1355-1356.
45. 45 Crone, N.E. and Reder, A.T. Severe tetanus in immunized patients with high anti-tetanus titers. Neurology 1992, 42, 761-764.
46. 46 Moraes-Pinto, M.I., Oruamabo, R.S. and Igbagiri, F.P. et al. Neonatal tetanus despite immunization and protective antitoxin antibody. J. Infect. Dis. 1995, 171, 1076-1077.